4th May 2012
Astra is looking to pay $1.2bn (£740m) for Ardea, which has a promising gout drug in Phase 3 trials. That said, the business currently has little in the way of revenues and is forecast to make a loss of more than £80m this year. The earliest its drug can be on the market, always assuming it actually passes this final testing phase, would be 2015.
For its part, Glaxo is set to pay $2.3bn for Human Genome Sciences (HGS), whose latest drug has successfully passed its Phase 3 trials; although initial sales have disappointed, the business continues to make losses and its share price has fallen 75%. Glaxo is already a 50/50 partner on this drug with HGS, however, and would appear to be exploiting short-term price weakness in the belief it has good long-term potential.
On the face of it, the Glaxo deal looks to carry less risk as HGS's main product has already passed its trials – good news in itself for an industry that has been struggling for some time to find new drugs to bring to market – and Glaxo knows the product well as a result of the existing partnership. However, the price tags on both companies look exorbitant.
Once the adjustment is made for the fact Glaxo already receives half the profits through its existing agreement, the group is paying 40x sales for HGS while, in Astra's case, sales are so negligible as to make any multiple completely meaningless. Furthermore, since neither acquisition target generates any profits, it is impossible to appraise either deal on any profit measure.
Since – at $7bn and $6bn respectively – Astra and Glaxo's cash generation is so enormous, neither deal is likely to make or break anyone's investment case for them. However, as a statement of intent, it is concerning for many pharma-heavy value investors, such as ourselves, and suggests the managements remain focused on sales growth rather than explicitly trying to achieve shareholder value.
This conclusion is (read more…)
More on Mindful Money:
To receive our free email newsletter sign up here.